Additionally, inhibiting IL-6/signal transducer and activator of transcription 3 (STAT3) signaling has been found to reduce I148M variant-mediated susceptibility to NAFLD [141]. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.